Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23751468 | 0.89 | OPRD1 (0.43) | OPRD1FPR2SIGMAR1CHRM2CHRM1 | |
| SCHEMBL23751469 | 0.89 | OPRD1 (0.43) | OPRD1FPR2SIGMAR1CHRM2CHRM1 | |
| SCHEMBL25339440 | 0.87 | GAA (0.42) | GAAFOLH1KMT2AMEN1CHRM3 | |
| SCHEMBL31291039 | 0.87 | GPR119 (0.48) | — | |
| SCHEMBL22764719 | 0.87 | GPR119 (0.48) | — | |
| SCHEMBL31598977 | 0.87 | GPR119 (0.48) | — | |
| SCHEMBL22765041 | 0.87 | GPR119 (0.48) | — | |
| SCHEMBL29508681 | 0.87 | GPR119 (0.48) | — | |
| SCHEMBL30543782 | 0.86 | MMP13 (0.39) | OPRD1GAAFOLH1KMT2AMEN1 | |
| SCHEMBL25340912 | 0.85 | MEN1 (0.44) | SIGMAR1KMT2AMEN1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220169636-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2022-06-02 | — | — | US | disclosed |
| EP-3980409-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210253559-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-08-19 | — | — | US | disclosed |
| WO-2020247429-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253559-A1 | PYRROLIDINE COMPOUNDS | PAH, OTC, PPOX | OPRD1 135/4885GAA 2638/4885FOLH1 407/4885 |
| US-20220169636-A1 | PYRROLIDINE COMPOUNDS | ADCYAP1R1, AVPR2, NPPA | OPRD1 1160/4885GAA 310/4885FOLH1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.